A Phase 3 Randomized Double-Blind Placebo-Controlled Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults with Elevated Lipoprotein(a) who have Established Atherosclerotic Cardiovascular Disease or Are at Risk for a First Cardiovascular Event ACCLAIM-Lp(a)

Brief description of study

The purpose of this study is to investigate the effect of lepodisiran on the reduction of major adverse cardiovascular events (MACE) in adults with elevated Lp(a) and established atherosclerotic cardiovascular disease (ASCVD) or who are at risk for a first cardiovascular (CV) event and provide additional evidence for the potential clinical benefits of Lepodisiran.

Clinical Study Identifier: s24-00145

ClinicalTrials.gov Identifier: NCT06292013

Principal Investigator: Holly F Lofton.

Other Investigator: Babak J. Orandi.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Clinical Research Studies

Brief description of study

Recruitment Status

Contact the research team to learn more about this study.

Recruitment Status

212-263-4432

646-754-7432